TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11340389

Group type: EXPERIMENTAL
Intervention: 2% dorzolamide
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 1% brinzolamide
Number of subjects: 41

Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 41
Study: 9679262

Group type: EXPERIMENTAL
Intervention: Structured symptom assessment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 48
Study: 7974179

Group type: EXPERIMENTAL
Intervention: 6 Gy/fraction (group A)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 7.5 Gy/fraction (group B)
Number of subjects: 165
Study: 2810468

Group type: EXPERIMENTAL
Intervention: Video-feedback training (VFT) group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Traditional training (TT) group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 798269

Group type: EXPERIMENTAL
Intervention: Plasminogen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31940376

Group type: EXPERIMENTAL
Intervention: Long decision aid (DA)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Short decision aid (DA)
Number of subjects: 3000
Study: 31525112

Group type: EXPERIMENTAL
Intervention: Automated metrics for speech intelligibility assessment
Number of subjects: 73
Study: 27859251

Group type: EXPERIMENTAL
Intervention: Paediatric fixed-dose combination (FDC) zidovudine/lamivudine/nevirapine (60/30/50 mg) tablet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Combined mixture of single-entity innovator products (reference product)
Number of subjects: 24
Study: 26075487

Group type: EXPERIMENTAL
Intervention: Cariprazine 3-6 mg/d
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Cariprazine 6-9 mg/d
Number of subjects: 446

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446
Study: 23548123

Group type: EXPERIMENTAL
Intervention: Zishentongluo (ZSTL)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Benazepril
Number of subjects: 45
Study: 21742106

Group type: EXPERIMENTAL
Intervention: TFG 0/1 prior to pPCI
Number of subjects: 8337

Group type: EXPERIMENTAL
Intervention: TFG 2 prior to pPCI
Number of subjects: 8337

Group type: EXPERIMENTAL
Intervention: TFG 3 prior to pPCI
Number of subjects: 8337
Study: 19627913

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (strength training and aerobic components), 5 days per week, with gradually increased intensity and duration.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (strength training and aerobic components)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No exercise intervention (control group)
Number of subjects: 0
Study: 16704693

Group type: EXPERIMENTAL
Intervention: Transpupillary thermotherapy (TTT) using an 810-nm Oculight diode laser with a fixed spot size covering the whole lesion.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (control group) with power set at zero during the same procedure.
Number of subjects: 25
Study: 15605617

Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg/day for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15530734

Group type: EXPERIMENTAL
Intervention: VR smoking cues
Number of subjects: 13

Group type: COMPARATOR
Intervention: VR neutral cues
Number of subjects: 13
Study: 11036827

Group type: EXPERIMENTAL
Intervention: Fish oil derived (n‐3) fatty acid supplementation (3‐6 capsules/day, 40 mg/kg body weight)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Olive/corn oil capsule supplement (control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 50
Study: 8847860

Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg once daily for 1 week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (once daily for 1 week)
Number of subjects: 40
Study: 1543845

Group type: EXPERIMENTAL
Intervention: Intraoperative TEE
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (no TEE)
Number of subjects: 57
Study: 3519142

Group type: EXPERIMENTAL
Intervention: Bovine lung heparin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Porcine intestinal mucosa heparin
Number of subjects: 43
Study: 3360858

Group type: EXPERIMENTAL
Intervention: Brand A
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Brand C
Number of subjects: 6

Group type: COMPARATOR
Intervention: Brands F and B
Number of subjects: 6
Study: 31933259

Group type: EXPERIMENTAL
Intervention: Re-resection of recurrent glioblastoma multiforme
Number of subjects: 39

Group type: COMPARATOR
Intervention: No re-resection (control group)
Number of subjects: 39
Study: 30099647

Group type: EXPERIMENTAL
Intervention: Educational lyric analysis
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Educational songwriting
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control
Number of subjects: 92
Study: 27466718

Group type: EXPERIMENTAL
Intervention: Isunakinra (5 mg/mL)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Isunakinra (20 mg/mL)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Isunakinra (5 mg/mL) and (20 mg/mL)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 74
Study: 26343102

Group type: EXPERIMENTAL
Intervention: Self-administered exercises based on Tuina techniques
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (Tuina exercises executed in points away from commonly-used acupuncture points)
Number of subjects: 69
Study: 23833362

Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin alone (Group-1): One drop 6 times/day for 3 days before surgery and one drop 4 times on the day of surgery
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin with flurbiprofen (Group-2): One drop 6 times/day for 3 days before surgery and one drop 4 times on the day of surgery, plus flurbiprofen one drop 4 times/day for 3 days before and on the day of surgery
Number of subjects: 50
Study: 21912022

Group type: EXPERIMENTAL
Intervention: Cyclo 10 mg/kg monthly for six months then every two months for 12 months (Group I)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Cyclo 5 mg/kg monthly for six months then every two months for 36 months (Group II)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Cyclo 10 mg/kg (Group I)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Cyclo 5 mg/kg (Group II)
Number of subjects: 117
Study: 19167276

Group type: EXPERIMENTAL
Intervention: 200mg (E)-entacapone tablet formulation
Number of subjects: 36
Study: 17140457

Group type: EXPERIMENTAL
Intervention: Yoga (YG, n = 146)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Wait list control (WL, n = 145)
Number of subjects: 291
Study: 16095445

Group type: EXPERIMENTAL
Intervention: Propofol with remifentanil (1 microg kg‐1 remifentanil + 0.5 mg kg‐1 propofol)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propofol with alfentanil (10 microg kg‐1 alfentanil + 0.5 mg kg‐1 propofol)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propofol (0.75 mg kg‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propofol with alfentanil and Propofol with remifentanil
Number of subjects: 24
Study: 11549477

Group type: EXPERIMENTAL
Intervention: Tubeless PCN
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard PCN
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mini-PCN
Number of subjects: 30
Study: 9768926

Group type: EXPERIMENTAL
Intervention: Antegrade mild hypothermic blood cardioplegia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Retrograde mild hypothermic blood cardioplegia
Number of subjects: 20
Study: 7810806

Group type: EXPERIMENTAL
Intervention: Total IgG antibodies
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: IgG4 antibodies
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: IgG1 antibodies
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: IgG2 and IgG3 antibodies
Number of subjects: 131
Study: 3387717

Group type: EXPERIMENTAL
Intervention: Random walk model applied to treatment groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard analysis (difference between initial and final scores)
Number of subjects: 0
Study: 28215966

Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Femoral Nerve Block (FNB)
Number of subjects: 50
Study: 24592875

Group type: EXPERIMENTAL
Intervention: Ostracism condition (Cyberball manipulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inclusion condition (Cyberball manipulation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dispositional self-esteem
Number of subjects: 0
Study: 23993139

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum ssp infantis (Binf)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bifidobacterium animalis ssp lactis (Blac)
Number of subjects: 21
Study: 22101745

Group type: EXPERIMENTAL
Intervention: Pramipexole (PPX) 0.25-0.75 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Dual-release levodopa/benserazide (L/B) 125-375 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pramipexole (PPX)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Dual-release levodopa/benserazide (L/B)
Number of subjects: 39
Study: 19440101

Group type: EXPERIMENTAL
Intervention: Parents of adult children with bipolar disorder
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Parents of adult children with bipolar disorder with preexisting mental illness
Number of subjects: 145

Group type: COMPARATOR
Intervention: Comparison group (parents whose children did not have disabilities)
Number of subjects: 145
Study: 16552520

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical (MIS) approach via subvastus; 40 TKAs implanted.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard approach using OrthoPilot navigation; 40 TKAs implanted.
Number of subjects: 80
Study: 15351164

Group type: EXPERIMENTAL
Intervention: Early intervention strategy (angiography followed by revascularization)
Number of subjects: 1810

Group type: COMPARATOR
Intervention: Conservative care (ischaemia or symptom driven angiography)
Number of subjects: 1810
Study: 11318055

Group type: EXPERIMENTAL
Intervention: Training with slow speeds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training with fast speeds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulation of ball speed and size
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Performance across speed ranges
Number of subjects: 0
Study: 9456421

Group type: EXPERIMENTAL
Intervention: Neural network computation
Number of subjects: 95

Group type: COMPARATOR
Intervention: Holladay personalized calculation
Number of subjects: 95
Study: 7943709

Group type: EXPERIMENTAL
Intervention: 25-gauge spinal needle
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 27-gauge spinal needle
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 29-gauge spinal needle
Number of subjects: 300

Group type: COMPARATOR
Intervention: Larger bore needles (25- and 27-gauge)
Number of subjects: 300
Study: 3651281

Group type: EXPERIMENTAL
Intervention: suxamethonium 1 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: atracurium 0.4 mg kg‐1
Number of subjects: 0
Study: 31226405

Group type: EXPERIMENTAL
Intervention: Piano training
Number of subjects: 360

Group type: COMPARATOR
Intervention: Music listening instruction (active control)
Number of subjects: 360
Study: 28189481

Group type: EXPERIMENTAL
Intervention: Dynamic pulmonary function tests (PFTs) including peak expiratory flow (PEF), forced vital capacity (FVC), forced expiratory volume in one second (FEV1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Maximum static airway pressures (MIP, MEP)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Correlation of MIP%p and MEP%p
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Within-subject coefficients of variation (CV) for successive measures
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Transition from Brooke score category 4 to category 5
Number of subjects: 64
Study: 26380308

Group type: EXPERIMENTAL
Intervention: Instructor-led group protocol
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Pedometer
Number of subjects: 736

Group type: COMPARATOR
Intervention: Control group (135 active participants)
Number of subjects: 736
Study: 23963471

Group type: EXPERIMENTAL
Intervention: High-rate rTMS (10 Hz, 600 pulses in 10 trains, delivered to the hot spot of the right abductor digiti minimi, 3 sessions on alternate days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-rate rTMS
Number of subjects: 100
Study: 21385294

Group type: EXPERIMENTAL
Intervention: Home-based peer support with maternal-infant interaction teaching (12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 19196814

Group type: EXPERIMENTAL
Intervention: Inhaled beclometasone (200 microg day(‐1)) + Theophylline (400 mg day(‐1))
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Theophylline (400 mg day(‐1))
Number of subjects: 68

Group type: COMPARATOR
Intervention: Inhaled beclometasone (200 microg day(‐1))
Number of subjects: 68
Study: 17848668

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily)
Number of subjects: 9898

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 9898

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9898
Study: 15103566

Group type: EXPERIMENTAL
Intervention: Immunonutrition solution containing arginine, nucleotides, and polyunsaturated fatty acids
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isocaloric solution
Number of subjects: 30
Study: 11339730

Group type: EXPERIMENTAL
Intervention: Intraosseous infusion using the bone injection gun (BIG)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Saphenous vein cutdown
Number of subjects: 13
Study: 9072603

Group type: EXPERIMENTAL
Intervention: Post-intercourse prophylaxis (group 1, 70 patients)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Daily prophylaxis (group 2, 65 patients)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Post-intercourse prophylaxis (group 1)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Daily prophylaxis (group 2)
Number of subjects: 135
Study: 7701881

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide cream (Microcid)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Fusidic acid cream/gel (Fucidin)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 256
Study: 3427696

Group type: EXPERIMENTAL
Intervention: Cefoxitin 2 g IV every 8 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefotaxime 2 g IV every 8 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moxalactam 2 g IV every 8 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aztreonam 2 g IV every 8 hours
Number of subjects: 20
Study: 31398135

Group type: EXPERIMENTAL
Intervention: Q-learning-based in-vehicle learning system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-stage deployment solution for PHEV power management applications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neural network (NN) for predicting battery state-of-charge (SoC)
Number of subjects: 0
Study: 29540445

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) 2.4 g per day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 26883688

Group type: EXPERIMENTAL
Intervention: fesoterodine with topical vaginal estrogen
Number of subjects: 23

Group type: COMPARATOR
Intervention: fesoterodine alone
Number of subjects: 23
Study: 23855018

Group type: EXPERIMENTAL
Intervention: Mindful eating intervention (MB-EAT-D)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Diabetes self-management education (DSME) 'Smart Choices' (SC)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both MB-EAT-D and SC
Number of subjects: 52
Study: 22789840

Group type: EXPERIMENTAL
Intervention: Daytime napping
Number of subjects: 20

Group type: COMPARATOR
Intervention: Controlled activity
Number of subjects: 20
Study: 20044764

Group type: EXPERIMENTAL
Intervention: D‐J stenting (Group A)
Number of subjects: 184

Group type: COMPARATOR
Intervention: No D‐J stenting (Group B)
Number of subjects: 184
Study: 17764471

Group type: EXPERIMENTAL
Intervention: Electronic prompt in dispensing software
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no electronic prompt)
Number of subjects: 150
Study: 16092048

Group type: EXPERIMENTAL
Intervention: Diabetic subjects without complications (n = 65)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Nondiabetic subjects (n = 38)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Diabetic subjects with retinopathy (n = 29)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Diabetic subjects with both retinopathy and nephropathy (n = 25)
Number of subjects: 157
Study: 12420256

Group type: EXPERIMENTAL
Intervention: Propofol 0.25 mg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 10328274

Group type: EXPERIMENTAL
Intervention: Rectal-scalp temperature difference greater than 4 degrees C; Mean = 6.7, Range = 6.0-7.4; At the time of clinical brain death
Number of subjects: 12

Group type: COMPARATOR
Intervention: No intervention; Control group of survivors
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rectal-abdomen and rectal-mastoid temperature differences; No specific values reported
Number of subjects: 12
Study: 8617696

Group type: EXPERIMENTAL
Intervention: SMD subjects with rocking or thumb sucking
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SMD subjects
Number of subjects: 12
Study: 1566985

Group type: EXPERIMENTAL
Intervention: Through-the-Tuohy (needle within needle) approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sequential siting in separate spaces
Number of subjects: 100
Study: 4051157

Group type: EXPERIMENTAL
Intervention: Oral dantrolene 1.5 mg/kg administered orally 4 hours pre-operatively
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no dantrolene)
Number of subjects: 40
Study: 30874324

Group type: EXPERIMENTAL
Intervention: Bed and bedside chair pressure sensors linked to radio pagers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29045283

Group type: EXPERIMENTAL
Intervention: Immediate ART initiation
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Delayed ART initiation
Number of subjects: 1000
Study: 24293583

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) + Methotrexate (MTX)
Number of subjects: 0
Study: 22776567

Group type: EXPERIMENTAL
Intervention: Optimized acupuncture therapy
Number of subjects: 945

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 945

Group type: COMPARATOR
Intervention: Shallow acupuncture
Number of subjects: 945
Study: 20716665

Group type: EXPERIMENTAL
Intervention: Oral probiotic
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 16962799

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 16294072

Group type: EXPERIMENTAL
Intervention: Prone positioning (N = 21, kept prone for at least 8 hours and a maximum of 23 hours per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supine positioning (N = 19, positioned according to standard care guidelines)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 40
Study: 12173675

Group type: EXPERIMENTAL
Intervention: Stage-matched intervention
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Standard care intervention
Number of subjects: 196

Group type: COMPARATOR
Intervention: Mismatched intervention
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 196
Study: 9803707

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Supportive counseling (SC)
Number of subjects: 24
Study: 7986667

Group type: EXPERIMENTAL
Intervention: 20 mg amlodipine racemate
Number of subjects: 18
Study: 2663318

Group type: EXPERIMENTAL
Intervention: 5 mg/kg ibuprofen
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 10 mg/kg ibuprofen
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 10 mg/kg acetaminophen
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 29659413

Group type: EXPERIMENTAL
Intervention: Smartphone application for AED delivery
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no application)
Number of subjects: 61
Study: 28398950

Group type: EXPERIMENTAL
Intervention: Ketone ester drink
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 12
Study: 26414724

Group type: EXPERIMENTAL
Intervention: Placental matrix‐derived mesenchymal stem cells (PM‐MSCs) injection
Number of subjects: 5
Study: 23128664

Group type: EXPERIMENTAL
Intervention: zoledronic acid
Number of subjects: 179

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 179
Study: 21996194

Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 18510173

Group type: EXPERIMENTAL
Intervention: Oral Genetaxyl at doses of 60 mg/m2, 120 mg/m2, and 180 mg/m2 with 10 mg/kg of oral cyclosporin A
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous Genetaxyl (175 mg/m2, 3-h infusion)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intravenous Genaxyl (175 mg/m2, 3-h infusion)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Generic i.v. paclitaxel (Genaxol, containing 50% CrEL; 175 mg/m2, 3-h infusion)
Number of subjects: 9
Study: 16585987

Group type: EXPERIMENTAL
Intervention: Twice daily topical 1% pimecrolimus cream
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Twice weekly narrowband UVB
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination therapy (pimecrolimus + narrowband UVB)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study: 15310050

Group type: EXPERIMENTAL
Intervention: Three levels of critical incident stress intervention
Number of subjects: 18